<DOC>
	<DOCNO>NCT00406978</DOCNO>
	<brief_summary>This study evaluate safety efficacy association Melphalan/ Prednisone/Thalidomide/Defibrotide ( MPTD ) salvage treatment advance refractory myeloma patient . This association might increase response rate achieve oral MPT regimen</brief_summary>
	<brief_title>Melphalan , Prednisone , Thalidomide Defibrotide Relapsed Multiple Myeloma Patients</brief_title>
	<detailed_description>Defibrotide ( DF ) novel orally bioavailable polydisperse oligonucleotide anti-thrombotic anti-adhesive effect , show active various microangiopathies , include treatment prophylaxis veno-occlusive disease . While DF minimal inhibitory effect multiple myeloma ( MM ) cell isolates , show single agent activity human MM xenograft SCID/NOD mice markedly increase responsiveness MM cytotoxic agent , include melphalan , cyclophosphamide dexamethasone model . DF might thus enhance response rate Melphalan , Prednisone Thalidomide , protect prothrombotic state see combination treatment MM . In multicenter , open label , non-randomised phase I/II trial , dose safety efficacy melphalan , prednisone , thalidomide , DF ( MPTD ) determine pts relapsed/refractory MM . Primary refractory pt receive therapeutic anticoagulation exclude . Oral melphalan administer 0,25 mg/Kg D1-4 , oral prednisone 1,5 mg/kg D 1-4 , thalidomide deliver 50 mg D1-35 cycle 1 100 mg cycle 2 cycle 6 . Level + 1 DF = 17 mg/Kg i.v . 2.4 g p.o . D1-4 , follow 1.6 g p.o . D 35 Level + 2 DF = 34 mg/Kg i.v . 4.8 g p.o . D 1-4 , follow 3.2 g p.o . D 35 Level + 3 DF = 51 mg/Kg i.v . 7.2 g p.o . D 1-4 , follow 4.8 g p.o . D 35 . Each course repeat every 35d total 6 course DVT prophylaxis use .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Defibrotide</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : Patient legally consent age define local regulation . Patient , investigator ( ) opinion willing able comply protocol requirement . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Female patient either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male patient agree use acceptable method contraception ( i.e. , condom abstinence ) duration study . Patient previously diagnose multiple myeloma base standard criterion ( see Section 13.2 ) . Patient relapse one line treatment less three line , include highdose chemotherapy stem cell support , conventional polichemotherapy , thalidomide melphalanbased regimen Patient primary refractory disease consider eligible Patient measurable disease , define follow : quantifiable serum monoclonal protein value ( generally , necessarily , great 1 g/dL IgG MProtein great 0.5 g/dL IgA MProtein ) , applicable , urine lightchain excretion &gt; 200 mg/24 hour . Patient Karnofsky performance status ≥60 % . Patient lifeexpectancy &gt; 3 month . Patient follow laboratory value within 14 day Baseline ( day 1 Cycle 1 , study drug administration ) : Platelet count ≥90 x 109/L without transfusion support within 7 day test . Absolute neutrophil count ( ANC ) ≥ 1.00 x 109/L without use growth factor Corrected serum calcium ≤14 mg/dL ( 3.5 mmol/L ) . Aspartate transaminase ( AST ) : ≤ 2.5 x upper limit normal ( ULN ) . Alanine transaminase ( AST ) : ≤ 2.5 x ULN . Total bilirubin : ≤ 1.5 x ULN . Calculated measured creatinine clearance : ≥20 mL/minute Patients meet follow exclusion criterion enrol study . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant beast feeding female . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Use concomitant standard/experimental antimyeloma drug therapy Known positive HIV active infectious hepatitis , type B C Other concurrent anticoagulation treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>MYELOMA</keyword>
	<keyword>THALIDOMIDE</keyword>
	<keyword>DEFIBRODITE</keyword>
</DOC>